脾边缘区淋巴瘤的治疗进展

发布时间：2018-06-23 13:56

本文选题：脾边缘区淋巴瘤 + 脾切除　；参考：《中国实验血液学杂志》2017年02期

【摘要】：脾边缘区淋巴瘤(splenic marginal zone lymphoma,SMZL)是一种罕见的惰性B细胞非霍奇金淋巴瘤,主要临床表现为脾肿大,外周血淋巴细胞增多及正常血细胞减少。瘤细胞免疫组织化学为CD45,CD20,CD79a,PAX5,IgD和BCL-2阳性。既往常用的治疗方案为脾切除和单纯化疗,近年来发现利妥昔单克隆抗体联合化疗方案的疗效较以前有显著的提高,已成为临床的一线治疗方案。IFN-α单药或联合病毒唑可用于治疗合并HCV感染的患者。此外,一些新型靶向药物如Bruton酪氨酸激酶抑制剂,NOTCH信号通路抑制剂,CAL-101(磷脂酰肌醇PI3K抑制剂)等正在临床试验当中。本文就脾边缘区淋巴瘤的治疗方案最新研究进展作一综述。
[Abstract]:Splenic marginal region lymphoma (splenic marginal zone lymphomonas) is a rare inert B-cell non-Hodgkin 's lymphoma. The main clinical manifestations are splenomegaly, peripheral blood lymphocyte proliferation and normal blood cell decline. Immunohistochemistry of tumor cells was positive for CD45, CD20, CD79, PAX5, IgD and BCL-2. In recent years, it was found that the therapeutic effect of rituximab combined with chemotherapy was significantly improved. IFN- 伪 single drug or combined virazole can be used to treat patients with HCV infection. In addition, some novel targeted drugs, such as Bruton tyrosine kinase inhibitor (Bruton tyrosine kinase inhibitor), inositol PI3K inhibitor, and so on, are being tested in clinical trials, such as CAL-101 (phosphatidylinositol PI3K inhibitor). This article reviews the latest research progress in the treatment of splenic marginal region lymphoma.
【作者单位】：天津医科大学肿瘤医院国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室天津市恶性肿瘤临床医学研究中心;
【基金】：国家自然科学基金(31301161、81270603、81570201) 天津市应用基础与前沿技术研究计划(13JCYBJC22800)
【分类号】：R733.1

【相似文献】